Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alutard SQ allergen immunotherapy in Chinese children with mite-induced allergic rhinitis and/or asthma
ChiCTR2000034714Phase 4Not yet recruiting
- Sponsor
- Affiliated Children's Hospital, Capital Institute of Pediatrics
- Start
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of alutard-sq in allergic rhinitis (AR) and asthma (2 arms), sponsored by Affiliated Children's Hospital, Capital Institute of Pediatrics. Primary endpoints: Serum specific IgE test of 19 allergens at 48 months, Saliva and serum IgG4 test of Der p 1 and Der p 2 at 48 months and 3 more. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on ChiCTR2000034714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034714.